Universe Pharmaceuticals (UPC) - Long-Term Debt to Capital
Universe Pharmaceuticals (UPC) generates revenue through the sale of plant-based medications for the gastrointestinal and respiratory tracts via hospitals and its own retail outlets. This chart on the GURU.Markets platform, with a value of 0.04, links commercial success to production facilities in China that rely on a local raw material base. Business stability is bolstered by a staff of experienced researchers and pharmacists, ensuring there is no talent shortage.
%20Long-Term%20Debt%20to%20Equity&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261030&filename=GURU_Markets_-_UPC_-_Universe-Pharmaceuticals_-_Long-Term-Debt-to-Equity "Universe Pharmaceuticals INC (UPC): Long-Term Debt to Capital Coefficient from 07/04/2022 to 10/30/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Universe Pharmaceuticals (UPC)
The stable cash flow from the sale of traditional Chinese medicine at Universe Pharmaceuticals (UPC) minimizes the need for aggressive borrowing. The current long-term debt-to-equity ratio stands at 0.04. This ratio measures the proportion of long-term leverage relative to the business's own equity. A low value indicates financial autonomy and high resilience to default. Investors view such a structure as a conservative growth strategy.